CompletedNot Applicable

Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma

50 participantsStarted 2011-12

Plain-language summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with Epstein-Barr virus positive Hodgkin lymphoma.

Who can participate

Age range9 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of Hodgkin lymphoma (HL) meeting the following criteria: * Epstein-Barr virus-positive (EBV+) HL as assessed by positive EBV serology, elevated levels of EBV genome in the blood or tumor tissue following quantitative polymerase chain reaction (PCR) and/or evidence of EBV positivity of pathology samples (EBER+ or LMP+) and, when possible, mixed cellular histology * Young age (\< 10 years) at diagnosis * Presence of hemophagocytic lymphohistiocytosis (HLH) PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

What they're measuring

Presence of germline ITK mutations

Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein

Correlation between ITK mutations with specific clinical or histopathological features of HL

Trial details

NCT IDNCT01490801

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Lymphoma trials